• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immuneering Corporation - Class A Common Stock (NQ:IMRX)

    4.470 +0.010 (+0.22%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 616,024
    Open 4.410
    Bid (Size) 4.450 (100)
    Ask (Size) 4.500 (3,500)
    Prev. Close 4.460
    Today's Range 4.400 - 4.505
    52wk Range 2.900 - 10.08
    Shares Outstanding 25,938,064
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Corporation Announces Grants of Inducement Awards
    From Immuneering Corporation
    Via GlobeNewswire

    Performance

    YTD
    -32.5%
    -32.5%
    1 Month
    +0.7%
    +0.7%
    3 Month
    -19.5%
    -19.5%
    6 Month
    -6.5%
    -6.5%
    1 Year
    +5.4%
    +5.4%

    More News

    Read More
    News headline image
    Immuneering Appoints Andrew Gengos as Chief Financial Officer
    From Immuneering Corporation
    Via GlobeNewswire
    IMRX Stock Closed Over 20% Higher Today: Here’s Why ↗
    Via Stocktwits
    News headline image
    Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
    From Immuneering Corporation
    Via GlobeNewswire
    Friday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present at the Leerink Global Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From Immuneering Corporation
    Via GlobeNewswire
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    Get insights into the top gainers and losers of Thursday's pre-market session. ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire

    Frequently Asked Questions

    Is Immuneering Corporation - Class A Common Stock publicly traded?
    Yes, Immuneering Corporation - Class A Common Stock is publicly traded.
    What exchange does Immuneering Corporation - Class A Common Stock trade on?
    Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Immuneering Corporation - Class A Common Stock?
    The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market
    What is the current price of Immuneering Corporation - Class A Common Stock?
    The current price of Immuneering Corporation - Class A Common Stock is 4.470
    When was Immuneering Corporation - Class A Common Stock last traded?
    The last trade of Immuneering Corporation - Class A Common Stock was at 07/22/26 04:00 PM ET
    What is the market capitalization of Immuneering Corporation - Class A Common Stock?
    The market capitalization of Immuneering Corporation - Class A Common Stock is 115.94M
    How many shares of Immuneering Corporation - Class A Common Stock are outstanding?
    Immuneering Corporation - Class A Common Stock has 116M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.